Intralymphatic GAD-alum (Diamyd(R)) improves glycaemic control in Type 1 diabetes with HLA DR3-DQ2. Nowak C, Lind M, Sumnik Z, Pelikanova T, et al. J Clin Endocrinol Metab 2022 Jun 6. pii: 6602344. doi: 10.1210.

Read + Share

Amedeo Smart

Independent Medical Education

Nowak C, Lind M, Sumnik Z, Pelikanova T, et al. Intralymphatic GAD-alum (Diamyd(R)) improves glycaemic control in Type 1 diabetes with HLA DR3-DQ2. J Clin Endocrinol Metab 2022 Jun 6. pii: 6602344. doi: 10.1210.
PMID: 35665810